HachUltra Excellence in Process Analytics
RUS ENG   
  Find



Home /

Technical Papers

Achieving ROI from Ozone Sanitizing
Advantages of the ORBISPHERE Ozone Sensor
 
 
 

 

Ozone is an extremely fast and efficient oxidizer commonly used as a microbial disinfectant in pharmaceutical grade water systems. The main benefits of ozone as a disinfectant include the fact that:

• Ozone is extremely efficient, acting 3,000 times faster than chlorine
• Ozone is easily removed after the disinfection process is complete
• Ozone reduces residual TOC levels
• Ozone inherently reduces endotoxin levels
• Ozone oxidizes inorganic materials (nitrites, sulfides, etc.)

As a result, ozonation of pharmaceutical water systems is now the preferred method for disinfection by a number of leading pharmaceutical manufacturers.

 

 

 

To download the complete paper click on this link.

Selecting Sample Points
PharmaTechnology
 

by Joe Gecsey, Life Sciences Application Manager, Hach Ultra

 

 

"Monitoring airborne particles in clean zones is not just a regulatory issue; it's a question of quality."

Selecting Sample Points - PharmaTechnology

Detection and Control in WFI and PW Systems
Pharmaceutical Engineering/ISPE
 

by Dr. Hans-Walter Motzkus and Joe Gecsey

 

 

This case study presents early contamination detection in an established WFI and PW system through the use of on-line particle counters.

A New Approach to TOC Analysis Using Closed-Loop Photocatalytic Oxidation

Sampling and preparation techniques key to success in meeting new requirement for particulate analysis in SVPs
European Journal of Parenteral & Pharmaceutical Sciences 2005
 

by Joe Gecsey and Tony Harrison
Life Science Application Manager and Pharmaceutical Market Manager, Hach Ultra Analytics, Chesterfield, UK

 

 

Effective 1 April 2005, Version 5.1 of the European Pharmacopoeia requires that dosage forms ofparenterals less than 100ml be inspected for liquidborne particles using an optical particle counteror, in certain case, an optical microscope. Previously the EP required particulate analysis only fordosage forms greater than 100ml. The test procedure for Small Volume Parenterals (SVPs) incontainers under 25ml has been in place within the EP for a number of years [Section 2.9.19, Test1.B] but until Edition 5.1 testing was not required for dosage forms equal to or less than 100ml. Thisrevision brings testing of European parenteral products more closely into harmony with the existingAmerican USP, Japanese JP and Korean KP regulations.

HachUltra
Official and exclusive representation